Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 7/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 3/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.35 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738691 | 1.00 | BRD9 (0.38) | BRD9BRPF1BRD4NCF1ADAM17 | |
| SCHEMBL1738321 | 0.81 | FPR2 (0.43) | BRD9BRPF1BRD4NCF1ROCK2 | |
| SCHEMBL1737767 | 0.81 | FPR2 (0.43) | BRD9BRPF1BRD4NCF1ROCK2 | |
| SCHEMBL1740165 | 0.81 | FPR2 (0.43) | BRD9BRPF1BRD4NCF1ROCK2 | |
| SCHEMBL6431223 | 0.80 | SLC6A2 (0.53) | ROCK2DRD2DRD4DRD3 | |
| SCHEMBL6434969 | 0.79 | ROCK2 (0.44) | BRD9BRPF1BRD4NCF1ROCK2 | |
| SCHEMBL1738368 | 0.79 | NCF1 (0.38) | BRD9BRPF1BRD4NCF1ROCK2 | |
| SCHEMBL1738815 | 0.79 | NCF1 (0.38) | BRD9BRPF1BRD4NCF1ROCK2 | |
| SCHEMBL1737661 | 0.79 | NCF1 (0.38) | BRD9BRPF1BRD4NCF1ROCK2 | |
| SCHEMBL27686637 | 0.79 | NCF1 (0.36) | BRD9BRPF1BRD4NCF1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727794-B1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | PFIZER PROD INC (US) | 2011-11-16 | — | — | EP | claimed |
| US-20110263484-A1 | SINGLE CHAIN FC TYPE III INTERFERONS AND METHODS OF USING SAME | ZYMOGENETICS, INC. | 2011-10-27 | — | — | US | claimed |
| US-7479559-B2 | 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation | PFIZER INC. (US) | 2009-01-20 | — | — | US | disclosed |
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007026224-A2 | 5-HT1B ANTAGONIST COMPOSITION FOR DEPRESSION, ANXIETY AND COGNITION | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1727794-A1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | Pfizer Products Incorporated (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | PFIZER INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005090300-A1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | HTR1E, HTR1D, HTR1A | BRD9 3424/4885BRPF1 3541/4885BRD4 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.